![]() CDX 29 Jan 2007 Paid | Interim | A$1.18 Per Share |
29 Jul 2025 (In 3 days) Date | | - Cons. EPS | - EPS |
26 Feb 2025 Date | | - Cons. EPS | - EPS |
29 Nov 2024 Date | | - Cons. EPS | - EPS |
30 Aug 2024 Date | | - Cons. EPS | - EPS |
28 Aug 2024 Date | | - Cons. EPS | - EPS |
![]() CDX 29 Jan 2007 Paid | Interim | A$1.18 Per Share |
29 Jul 2025 (In 3 days) Date | | - Cons. EPS | - EPS |
26 Feb 2025 Date | | - Cons. EPS | - EPS |
29 Nov 2024 Date | | - Cons. EPS | - EPS |
30 Aug 2024 Date | | - Cons. EPS | - EPS |
28 Aug 2024 Date | | - Cons. EPS | - EPS |
Medical Devices Industry | Healthcare Sector | Mr. Craig R. Cooper BEC, L.L.B. CEO | ASX Exchange | AU0000015729 ISIN |
Australia Country | - Employees | 29 Jan 2007 Last Dividend | 17 Feb 2022 Last Split | 9 Nov 2005 IPO Date |
CardieX Limited is a notable player in the medical device industry, focusing on the development, manufacturing, and marketing of devices aimed at the management of cardiovascular health. With its operations spanning across the Americas, Europe, and the Asia Pacific, the company has marked its presence on a global scale. Originally operating under the name AtCor Medical Holdings Limited, the company underwent a rebranding process to become CardieX Limited in June 2018. Since its inception in 1994 in Sydney, Australia, CardieX has dedicated itself to advancing cardiovascular health through innovative technology.
The cornerstone of CardieX Limited's product offering is the SphygmoCor technology, a patented vascular biometric system. This cutting-edge technology measures arterial health by collecting digital vascular biomarkers through novel sensors. It is designed to provide comprehensive insights into the cardiovascular system, making it a valuable tool for healthcare professionals in diagnosing and managing vascular health disorders.
In addition to SphygmoCor, CardieX offers a range of medical devices and vascular biomarkers specifically tailored for the management of hypertension, cardiovascular disease, and other vascular health issues. These products are developed with the aim of enhancing patient care and outcomes by providing accurate and actionable health data.
Understanding the growing demand for home-based healthcare solutions, CardieX has expanded its portfolio to include digital health products and wearables. These devices are designed for home health management, decentralized clinical trials, and remote patient monitoring, facilitating convenient and continuous care.
CardieX Limited's product and service range address a wide array of needs within the cardiovascular health management space, offering solutions for hospitals, clinics, research institutions, and pharmaceutical companies. Through its commitment to innovation and quality, CardieX aims to improve patient outcomes and the overall management of cardiovascular diseases globally.